Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update
Progenity, Inc. (Nasdaq: PROG) announced plans to report its financial results for Q4 and the full year ending December 31, 2021, on March 28, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Progenity, Inc. (Nasdaq: PROG) announced plans to report its financial results for Q4 and the full year ending December 31, 2021, on March 28, 2022, after market close. The company will conduct a conference call at 4:30 p.m. Eastern to discuss the results and provide a corporate update. Interested parties can access the call via phone or a live webcast on Progenity's website, with a replay available for 60 days.
Details
News Market Reaction – PROG
The recorded move for PROG in the trading session of this news was +3.17%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30 p.m. Eastern / 1:30 p.m. Pacific that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-423-9813 for domestic callers or 201-689-8573 for international callers and entering the conference code: 13727360. A live webcast will be available online in the Investor Relations section of the company website at www.progenity.com and a replay will be available online for 60 days following the call.
About Progenity
Progenity, Inc. is a biotechnology company innovating in the fields of oral biotherapeutics, gastrointestinal health, and women’s health. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
For more information visit www.progenity.com, or follow the company on LinkedIn or Twitter.
Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
ir@progenity.com
(917) 741-7792
Media Contact
Kristin Schaeffer
CG Life
media@progenity.com
(858) 457-2436
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.